ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns.

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever ...

The firm added imsidolimab to its valuation assessment. Vanda’s “ambitious” long-term revenue goals look achievable, even without some late-stage assets, the analyst tells investors in a ...

AnaptysBio (NASDAQ:ANAB – Get Free Report) will likely be releasing its earnings data before the market opens on Monday, March 10th. Analysts expect AnaptysBio to post earnings of ($1.55) per share ...

our BDCA2 modulator Announced exclusive global license agreement with Vanda Pharmaceuticals to develop and commercialize imsidolimab, an IL-36R antagonist Year-end 2024 cash and investments of ~$ ...

The company entered into an exclusive global license agreement with AnaptysBio for imsidolimab, an IL-36 receptor antagonist, which could expand their anti-inflammatory portfolio. Vanda ...

Our anti-inflammatory portfolio, anchored by Ponvory, was strengthened with the addition of imsidolimab from Anaptys, an IL-36 receptor inhibitor for the treatment of generalized pustular psoriasis.

The planned NDA submissions for Tradipitant in motion sickness and the BLA filing for imsidolimab also represent near-term opportunities to expand VNDA's product portfolio. Additionally ...